<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936934</url>
  </required_header>
  <id_info>
    <org_study_id>HospitalCG</org_study_id>
    <nct_id>NCT02936934</nct_id>
  </id_info>
  <brief_title>Comparison of Adverse Drug Reactions Associated for Oxycodone and Morphine in Postoperative Pain After Abdominal Hysterectomy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Civil de Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Civil de Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is compare adverse reactions associated with oxycodone and&#xD;
      morphine for the treatment of postoperative pain after abdominal hysterectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized single-blind study, was performed to compare the adverse reactions associated&#xD;
      with oxycodone and morphine in patients undergoing abdominal hysterectomy.&#xD;
&#xD;
      process:&#xD;
&#xD;
        1. A clinical history of patients candidates to participate in the study will be developed.&#xD;
&#xD;
        2. If you meet the selection criteria will be held the invitation to participate in the&#xD;
           study, reading the letter under information&#xD;
&#xD;
      Patients who agree to participate in the study will be managet during the surgical procedure:&#xD;
&#xD;
      15 mg mixed blockade with bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg&#xD;
      intravenously during surgery metamizol 3) After the surgical procedure (immediate&#xD;
      postoperative)&#xD;
&#xD;
      • the patient to group A or B (randomization) is assigned, masking infusions and allocation&#xD;
      will be conducted by an outside person who will test an additional record the names of the&#xD;
      patients and the drug administered.&#xD;
&#xD;
      A bolus of oxycodone or morphine 10% calculated dose for intravenous infusion 0.075mg&#xD;
      intravenous palonosetron prophylaxis of emesis Detection and assessment of severity of&#xD;
      adverse drug reactions will be conducted by an interview that will be at 0,1,2,6,12 and 24&#xD;
      hours after the onset of analgesia. Instrument designed for the detection of RAM will be used&#xD;
      and classify its severity according to common terminology criteria for adverse events&#xD;
      (CTCAE). Futhermore, measuring systemic blood pressure, heart rate, oxygen saturation will be&#xD;
      performed through the use of Nihon Kohden monitor (model BSN-2301K). Pain assessment will be&#xD;
      made by the numerical scale (NRS). The researcher responsible for the detection and&#xD;
      assessment of adverse reactions to opioids and others determinations, remain mowed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse drug reactions (questionnaire)</measure>
    <time_frame>24 hours</time_frame>
    <description>Nausea, vomiting, respiratory depression, dizziness, headache, sedation, pruritus and anaphylaxis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain (Numeric Pain Rating Scale)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic blood pressure (mmHg) (physiological parameter)</measure>
    <time_frame>24 hours</time_frame>
    <description>Monitor Nihon Kohden BSM-2301K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (physiological parameter)</measure>
    <time_frame>24 hours</time_frame>
    <description>Monitor Nihon Kohden BSM-2301K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation (physiological parameter)</measure>
    <time_frame>24 hours</time_frame>
    <description>Monitor Nihon Kohden BSM-2301K</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multimodal analgesia to morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multimodal analgesia to oxycodone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Interventions pre-specified to be administered to participants:&#xD;
Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery&#xD;
Intravenous infusion:&#xD;
200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Interventions pre-specified to be administered to participants:&#xD;
Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery&#xD;
Intravenous infusion:&#xD;
150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours.</description>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for abdominal hysterectomy&#xD;
&#xD;
          -  Signing for informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients used with MAO inhibitor drugs (&lt;14 days before surgery)&#xD;
&#xD;
          -  History of substance abuse&#xD;
&#xD;
          -  Hypersensitivity to opioids and others drugs of multimodal analgesia (metamizol and&#xD;
             lidocaine)&#xD;
&#xD;
          -  Pretreatment of any opioid (&lt;7/2 lives of the drug in question)&#xD;
&#xD;
          -  Chronic pain of any etiology (&gt; 6 months)&#xD;
&#xD;
          -  Diagnosis of bowel obstruction&#xD;
&#xD;
          -  Renal or hepatic insufficiency&#xD;
&#xD;
          -  Asthma, chronic obstructive pulmonary disease (COPD), and/ or hypothyroidism.&#xD;
&#xD;
          -  Patients requiring general anesthesia for surgical complications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>VIRGINIA A SANCHEZ, MD</last_name>
    <phone>3319837964</phone>
    <email>aleyda_sanmis7@hotmail.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Civil de Guadalajara</investigator_affiliation>
    <investigator_full_name>VIRGINIA ALEYDA SANCHEZ LOPEZ</investigator_full_name>
    <investigator_title>MD Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Adverse Drug Reaction</keyword>
  <keyword>Morphine</keyword>
  <keyword>Oxycodone</keyword>
  <keyword>Abdominal hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

